Scancell Share Discussion Threads

[bermudashorts] 20/9/2017 19:29

Sounds rough - hope it all went well

[chelsea35] 20/9/2017 19:22

My 11844, apols, had three days in hospitals and dentists, afraid it reads like i feel. Inanaco appreciate your replies, but it wasn"t meant to read like that, lol.

[bermudashorts] 20/9/2017 19:15

Gazza, he was quoting my 11850

[gazza] 20/9/2017 19:11

Inanaco, who are you quoting in your 11855?

[bermudashorts] 20/9/2017 19:03

Inanaco,

Ep Vantage is a specialist publication aimed at those working within the biotech/pharma and life sciences sectors. The report we were discussing concerned trials that had been halted by the FDA due to patient deaths and serious AE's. It didn't concern any approved drugs. Given the readership of EP Vantage, I think it's likely that most individuals reading that article would understand it.

Slightly different to one of America's leading newspapers publishing an article about approved drugs and using sensationalist language such as:- "tumors “just exploded” in size within two months of immunotherapy." It seems this is unproven and based on a report from some French researchers on a dozen or so patients. Jason Luke certainly seems to feel that there is no evidence to back up this theory.

Any patient receiving or about to receive treatment would surely find that very alarming and I don't think would appreciate that it's simply a theory. So I see a distinction between the two.

Either way though, I'm still not sure what point you're making. Why would I bump into the debate we had? I seem to remember it was about CAR T?

[inanaco] 20/9/2017 18:26

""""how is the average reader meant to grasp any of this? On the one hand patients need to be aware of the risks but should they be frightened by articles such as this when the 'risk' appears to be just a theory? """

for sure a connection ....

[bermudashorts] 20/9/2017 18:00

right - not sure what the connection is with my comment though.

[inanaco] 20/9/2017 17:39

/www.epvantage.com/Universal/View.aspx?type=Story&id=729139&isEPVantage=yes

[bermudashorts] 20/9/2017 17:14

You're going to have to remind me Inanaco - what debate was that? We've had a few.

[inanaco] 20/9/2017 16:40

Interesting Boom ... is this the moment you bump into what we had a debate on recently
about journalists ?

Ie ... CD123 antigen

[bermudashorts] 20/9/2017 16:03

....and interesting to see the role of the media in all of this. How many times has cancer been cured now according to the press? Almost weekly it seems. Looking at the article you provided link to above, how is the average reader meant to grasp any of this? On the one hand patients need to be aware of the risks but should they be frightened by articles such as this when the 'risk' appears to be just a theory?

Guess there is no answer to that - the field of medical ethics is actually more of a minefield IMO.

[gooosed] 20/9/2017 15:48

BS - Yes . . . . Innovators like Scancells very own Lindy Durrant - a hard act to follow but folks (such as Jason Luke) at the coal face tweeting their thoughts/findings is a useful resource to mere mortals.

[bermudashorts] 20/9/2017 15:34

goosed - interesting to see tweets from Jason Luke re. 'hyperprogression' -

"These analyses are potentially biased as retrospective. Phase 3 data in NSCLC & HNSCC do not show hyperprogression."

If nothing else, yet more proof that the whole field is still emerging with plenty not yet fully understood.

[inanaco] 20/9/2017 14:55

also from the RNS

Together with our existing cash resources and """"anticipated R&D tax credits """"


these funds will be used for: the manufacture and clinical development of Modi-1 in sarcomas, breast and ovarian cancers in a Phase 1/2 study; the filing and approval of US IND for SCIB1 checkpoint combination Phase 2 study in melanoma; further development of the product pipeline; and to support working capital requirements, which could add significant incremental value and support the Company's on-going commercial discussions.

[inanaco] 20/9/2017 14:44

Scancell is funded by Tax breaks for Funds .... EIS is one of them, small investors also received EIS shares. You can also invest via ISA ... all tax free

[chelsea35] 20/9/2017 14:21

Bermudashorts 11829, regardless of anybodies individual views, that is a very fine post. My own opinion, well the force has hardly been with us, the more checkpoint inhibitors the more we are needed in combination, even Bavarian Nordic are still confident in that space. Would love to us in a Phase 3 trial, dependant on Phase 1/2 results, i would love to see a fund offering subsidies and tax breaks for ""groundbreaking treatments"", Surely the odds are more favourable of finding new ""blockbusters from this very neglected pool.""

[drdobson] 20/9/2017 08:11

So INANs Multi National Commercial Property Empire including the Thai PENThouse are in fact SHEDS.Guffaw.
Pretends to be a scientist when he is BOB the builder.Guffaw.
Is he a ASTUTE investor or just a Walter Mitty.Guffaw.
Well NANA the Loz Empire STRIKES back and put you to the sword INTELLECTUALLY.
Are you bright or Thick as a bit of 2 x 2 SHED framing.
Bet you have SHED LOADs of SCLP shares but all bought at much higher levels than the ASTUTE as you go ALL IN.
PRICELESS. That you have go at LOZ and TOSH when they try and give sound advice and you just lie and cheat

[inanaco] 19/9/2017 20:29

as always ... Loz looks on the Bright side of life.. must be that big window ..Dazzling . or it has cooked his brain

[the real lozan] 19/9/2017 19:36

I don't suppose it might 'dawn-on-anyone' over on the over-excited M F F F, that the 'Job application' MAy be in order 'simply' to 'replace' someone who 'Jacked' ???
*WE* ALL know how quickly they re-act over there .... 2 + 2 MUST = 5

[the real lozan] 19/9/2017 15:46

P S-
*WE* know ONLY a FOOL would say "NO RISK here"
BUT
ONLY a BIGGER FOOL would believe it.

[the real lozan] 19/9/2017 15:44

BoB -
Never such 'an easy ride' some make it out-to-be
As we know = many try and many fail
BUT
ONLY A FOOL would say there is "NO RISK here"

[bermudashorts] 19/9/2017 15:40

Loz, I agree that it's frustrating and in a wider sense so typical of the issues faced by small UK bios. Fantastic innovation but such a battle to commercialisation.